Author:
Yamada Ikuhiro,Morizane Chigusa,Okusaka Takuji,Mizusawa Junki,Kataoka Tomoko,Ueno Makoto,Ikeda Masafumi,Okano Naohiro,Todaka Akiko,Shimizu Satoshi,Mizuno Nobumasa,Sekimoto Mitsugu,Tobimatsu Kazutoshi,Yamaguchi Hironori,Nishina Tomohiro,Shirakawa Hirofumi,Kojima Yasushi,Oono Takamasa,Kawamoto Yasuyuki,Furukawa Masayuki,Iwai Tomohisa,Sudo Kentaro,Okamura Keiya,Yamashita Tatsuya,Kato Naoya,Shioji Kazuhiko,Shimizu Kyouko,Nakagohri Toshio,Kamata Ken,Ishii Hiroshi,Furuse Junji,Yamada Ikuhiro,Morizane Chigusa,Okusaka Takuji,Mizusawa Junki,Kataoka Tomoko,Ueno Makoto,Ikeda Masafumi,Ozaka Masato,Okano Naohiro,Sugimori Kazuya,Todaka Akiko,Shimizu Satoshi,Mizuno Nobumasa,Sekimoto Mitsugu,Sano Keiji,Tobimatsu Kazutoshi,Katanuma Akio,Sakai Kenji,Yamaguchi Hironori,Nishina Tomohiro,Shirakawa Hirofumi,Kojima Yasushi,Oono Takamasa,Kawamoto Yasuyuki,Furukawa Masayuki,Iwai Tomohisa,Sudo Kentaro,Okamura Keiya,Yamashita Tatsuya,Yasuda Ichirou,Takahashi Hidenori,Kato Naoya,Shioji Kazuhiko,Shimizu Kyouko,Nakagohri Toshio,Kamata Ken,Ishii Hiroshi,Furuse Junji,
Abstract
AbstractIn the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup analysis focused on the elderly cohort of this trial. All 354 enrolled patients in JCOG1113 were classify into two groups; < 75 (non-elderly) and ≥ 75 years (elderly) group. We investigated the influence of age on the safety analysis, including the incidence of chemotherapeutic adverse events and the efficacy analysis, including OS. There were no remarkable differences in OS between the elderly (n = 60) and the non-elderly groups (n = 294). In the elderly group, median OS was 12.7 and 17.7 months for those who received GC (n = 20) and GS (n = 40), respectively. The prevalence of all-grade adverse events was similar between the elderly and the non-elderly groups. However, among the elderly group, Grade ≥ 3 hematological adverse events were more frequently observed in the GC arm than in the GS arm. The clinical outcomes of combination chemotherapy in elderly patients with advanced BTC were comparable to non-elderly patients. GS may be the more favorable treatment for elderly patients with advanced BTC.
Publisher
Springer Science and Business Media LLC